E3 PreliminaryPreliminaryPEM not requiredCase-ControlPeer-reviewedReviewed
Standard · 3 min
Bottom-up proteomics suggests an association between differential expression of mitochondrial proteins and chronic fatigue syndrome.
Ciregia, F, Kollipara, L, Giusti, L et al. · Translational psychiatry · 2016 · DOI
Quick Summary
This study looked at proteins in the mitochondria—the energy-producing structures in cells—to see if they differ in people with ME/CFS compared to healthy people. Researchers found that two specific proteins (ATPB and ACON) were higher in people with ME/CFS, suggesting these could potentially be useful markers to help identify the condition. The findings also hint that different subgroups of ME/CFS patients may have different protein patterns, which could eventually lead to more personalized treatments.
Why It Matters
This work contributes to growing evidence that mitochondrial dysfunction may underlie ME/CFS pathophysiology, offering potential diagnostic biomarkers that are noninvasive (saliva-based). The observation that different CFS patients show different protein patterns supports the emerging concept that ME/CFS comprises biologically distinct subgroups, which could enable future stratified diagnosis and targeted treatment development.
Observed Findings
ATP synthase subunit beta (ATPB) was upregulated in CFS patients compared to healthy controls
Aconitate hydratase (ACON) was upregulated in CFS patients compared to healthy controls
Malate dehydrogenase (MDHM) showed differential expression in initial mass spectrometry but this was not confirmed in the larger cohort
Expression levels of validated proteins varied when CFS patients were stratified by clinical features
Protein expression patterns were highest in CFS patients whose clinical features resembled the affected twin
Inferred Conclusions
Mitochondrial protein expression patterns, particularly ATPB and ACON, may serve as candidate biomarkers for CFS
CFS patient heterogeneity may reflect distinct molecular subtypes with different mitochondrial protein signatures
Proteomics-based biomarkers could potentially support CFS diagnosis and enable future development of subtype-specific treatments
Remaining Questions
Are ATPB and ACON expression changes stable across time, or do they fluctuate with disease activity and symptom severity?
Do these mitochondrial protein alterations reflect primary energy metabolism defects or secondary compensatory responses?
What This Study Does Not Prove
This study does not prove that elevated ATPB and ACON cause ME/CFS or that these proteins are causally linked to fatigue generation—correlation and mechanism remain unknown. It also does not establish whether these proteins represent a stable diagnostic marker across time, different tissues, or disease stages. The study cannot determine clinical utility for diagnosis without prospective validation and receiver-operating-characteristic analysis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.